Novartis stock had its Relative Strength (RS) Rating upgraded from 69 to 73 Monday -- a welcome improvement, but still below the 80 or better score you look for.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an RS Rating of at least 80 in the early stages of their moves. See if Novartis stock can continue to rebound and hit that benchmark.
See How IBD Helps You Make More Money In Stocks
Is Novartis Stock A Buy?
Novartis stock is trying to complete a double bottom with a 102.73 entry. See if the stock can clear the breakout price in heavy volume.
Top and bottom line growth moved higher last quarter. Earnings were up 17%, compared to 9% in the prior report. Revenue increased from -4% to 3%. Keep an eye out for the drug maker's next round of numbers on or around Jul. 18.
Novartis stock earns the No. 4 rank among its peers in the Medical-Ethical Drugs industry group. Indivior and Novartis are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
